Accelerate the progression of ethical and effective antigen specific
immunotherapies through the clinic, optimize the discovery of novel
targets and explore novel therapeutic approaches harnessing
combination therapies.Building on the success of the 2019 meeting, the
3rd Antigen Specific Immune Tolerance Summit (ASIT) returns to Boston
on February 25-27, 2020. The meeting will bring together industry
representatives from the fields of autoimmunity, allergy,
immuno-oncology and transplantation to tackle the complexities behind
autoimmune disorders head on. With momentum building for antigen
specific immunotherapies, ASIT 2020 is the only antigen specific
summit offering thought leading content to drive the field towards a
more precise and ethical antigen-specific approach to drug
development. Speakers: Kurt Griffin , Associate Professor, University
of South Dakota Sanford School of Medicine, Andreas Lutterotti , Head
of Experimental Therapies Research , University Hospital Zurich,
Stephen Miller, Co-Founder of Cour Pharmaceuticals; Professor of
Microbiology- Immunology, Northwestern University Medical School,
Aaron Michels Associate Professor of Pediatrics Medicine, and
Immunology, Barbara Davis Center for Diabetes, University of Colorado;
Chief Scientific Officer IM Therapeutics, Shahrokh Shabahang , Chief
Innovation Officer, AdiTxt Therapeutics, Kei Kishimoto , Chief
Scientific Officer, Selecta Biosciences, David Alleva , Executive
Director, Akston Biosciences, Giles Benichou , Associate Professor of
Surgery, Harvard Medical School, Senior Immunologist Massachusetts
General Hospital, Emilio Flano, Director and Head of Immunology
Discovery , Merck and Co, Matthias von Herrath , Vice President, Novo
Nordisk, Martin Roland, Head - Department of Neuroimmunology and
Multiple Sclerosis Research, University Hospital Zurich, Dolly Tyan
Professor, Emerita of Pathology Stanford, University School of
Medicine, Lawrence Steinman, Professor of Neurology, Neurological
Sciences and Pediatrics, Stanford University, Anne De Groot Founder,
Chief Executive Officer and Chief Scientific Officer, Epivax, Ben
Williams, Program Officer for the Type 1 Diabetes (T1D) Program,
Helmsley Charitable Trust, Giorgio Raimondi, Associate Scientific
Director for Transplant Immunology , John Hopkins School of Medicine,
Cory Berkland, Distinguished Professor, School of Pharmacy
Pharmaceutical Chemistry, University of Kansas, Todd Zion, President
and Chief Executive Officer, Akston Biosciences, Garth Ringheim,
Director Immunology Therapeutic Area, Clarivate Analysis, Curtis
Ruegg, President and Chief Executive Officer, Parvus Therapeutics,
Inc., Jack Ragheb, Senior Medical Fellow for Immunology in Global
Patient Safety, Eli Lilly and Co., Arpita Maiti, Executive Director
and Global Head, Global Head Pfizer, Kristina M. Harris Director,
Biomarker and Discovery Research, Immune Tolerance Network, Joshua
Sestak, President and Chief Executive Officer, Founder Orion
BioScience, Monali Manohar, Life Science Research Scientist Stanford,
University School of Medicine, Colin Dayan, Professor of Clinical
Diabetes and Metabolism Cardiff, University School of Medicine, David
Wraith, Director of the Institute of Immunology and Immunotherapy ,
University of Birmingham, Stephan Kontos, Founder and Chief Scientific
Officer, Anokion, Simi Ahmed, Director of Research and Lead of the
Immune Therapies Program, JDRF, Waldo Concepcion, Professor of Surgery
(Abdominal Transplantation) and of Pediatrics (Nephrology), Stanford
University Medical Center, Amy Rosenberg, Director - Therapeutic
Proteins and CDER, FDA
culture
702
Views
26/02/2020 Last update